Nobivac®
History of innovation
Elevating what is possible since 1979
For more than 40 years, we have been pushing the boundaries of vaccine science and development to help protect pets against serious infectious diseases.
Based on a strong scientific foundation, each new improvement in Nobivac vaccines has been designed to meet veterinarians’ evolving needs.
Recent highlights:
2022
Nobivac® Intra-Trac® Oral BbPi made effective oral vaccination against both Bordetella bronchiseptica and canine parainfluenza virus possible for the first time.
2021
Nobivac® DP PLUS / Nobivac® Puppy DP PLUS became the first vaccine capable of breaking through any level of parvovirus maternally derived antibody (MDA) in puppies as young as four weeks old.
Nobivac® Respira Bb became the first subunit injectable vaccine against Bordetella bronchiseptica for dogs.
Embracing a range of technologies
Throughout the history of Nobivac vaccines, we have been committed to discovering ways to broaden protection and leveraging all available technologies to advance what is possible in vaccination.
Breaking new ground in pet immunisation
Whether expanding the Nobivac vaccine portfolio to protect against more diseases, making vaccination itself easier or helping veterinarians educate pet owners on the importance of vaccination, we continue to lead the way in pet vaccination.
